Hike in Prices of Drugs Leaving Cancer Patient in Lurch

by Bidita Debnath on  January 29, 2017 at 10:55 PM Cancer News
RSS Email Print This Page Comment bookmark
Font : A-A+

Cancer patients are losing out on easy access to drugs due to hike in prices of life-saving medication by more than 1,000 percent and delay in the availability of new treatments, finds a new study.
 Hike in Prices of Drugs Leaving Cancer Patient in Lurch
Hike in Prices of Drugs Leaving Cancer Patient in Lurch

According to researchers, patients are suffering due to delay in the availability of new treatments and incomprehensible price rises for well-established therapies. The findings revealed that 20 treatments have risen ob over 100 percent in the last five years and two medicines - busulfan (used to treat leukaemia) and tamoxifen (breast cancer) - prices have increased by over 1000 percent.

They also found that some companies take over the supply of some generic cancer medicines and then raise the price progressively. "There is no value for patients if new cancer drugs are developed and approved but they are unable to benefit from them," said Markus Hartmann. "Between 2011 and 2016, the prices for some common drugs increased by more than 1000 percent.

At a time when the UK Cancer Drugs Fund is being re-examined because of the pressure caused by high prices, this is particularly worrying," said senior author Dr Andrew Hill from the University of Liverpool, UK. Paying these high prices puts undue strain on health systems and the long-term result could be negative consequences for disease progression and survival.

"We hope that, by explaining what we have found in the UK, other European countries will take note and protect themselves against these kinds of price rises," stated Dr Hill. The results show that several key cancer treatments could be manufactured for less than one percent of the prices charged. For example, tamoxifen, used to treat breast cancer, can be manufactured for less than two US dollars per month of treatment, and imatinib, used in the treatment of chronic myeloid leukaemia, can be produced for $54 per month.

The authors stated low costs could form the initial step in setting up programmes in low and middle income countries. "Showing that certain cancers could be treated for very low prices could transform the future of people with these cancers in very low-income countries where there are usually few or no treatment options," the researchers explained.

Source: ANI

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions
Advertisement

Recommended Reading

More News on:

Drug Toxicity Cancer and Homeopathy Cancer Facts Cancer Tattoos A Body Art Drugs Banned in India Common Lifestyle Habits that Cause Diseases Health Benefits of Dandelion Plant 

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Stay Connected

  • Available on the Android Market
  • Available on the App Store

News Category

News Archive